Market Overview:
The global pioglitazone HCL market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of diabetes, increasing awareness about diabetes and its treatment options, and growing demand for pioglitazone HCL in emerging markets. Based on type, the global pioglitazone HCL market is segmented into 15 mg, 30 mg, and 45 mg. The 30 mg segment is expected to account for the largest share of the global pioglitazone HCL market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. Based on application, the global pioglitazone HCl market is divided into industrial applications, pharmaceuticals applications, and other applications. The pharmaceuticals application segment accounted for majority share of the global pieglitazone hcl Market In 2017 And Is Expected To Grow At A Cagr Of Xx% From2018 To 2030 .
Product Definition:
Pioglitazone Hydrochloride is a thiazolidinedione antidiabetic drug used in the treatment of type 2 diabetes mellitus. It is marketed by Takeda Pharmaceuticals under the trade name Actos.
15 mg:
15 mg is used in the treatment of diabetic neuropathy, peripheral vascular disease, and retinopathy. It also helps to reduce the risk of stroke and heart attack. The drug was approved by FDA in 1995 for treating type 2 diabetes which was later on confirmed to be effective for diabetic patients suffering from cardiovascular diseases as well.
30 mg:
30 mg is used in the treatment of diabetic neuropathy, peripheral vascular disease, and retinopathy. It also helps to reduce the risk of stroke and heart attack. Increasing prevalence of diabetes has led to a rise in demand for insulin products which include biguanides such as phenformin & metformin that are used for treating type II diabetes.
Application Insights:
The industrial application segment accounted for the largest share of over 70.0% in 2017. Pioglitazone is used as a drug, which prevents and treats diabetes by increasing the sensitivity of insulin receptors in the body¢â‚¬â„¢s cells. It also reduces inflammation and improves blood vessels functioning, thereby lowering blood glucose levels and preventing type 2 diabetes mellitus. The pharmaceutical segment is expected to witness lucrative growth over the forecast period owing to its wide-spread usage as an anti-diabetic agent across various applications such as diabetic retinopathy, neuropathy, nephropathy & renal failure among others.
Other applications include use in smoking cessation programs along with Champix (zyban) or Chantix (Champix).
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of a large number of patients suffering from diabetes and high awareness levels about Pioglitazone HCL. In addition, increasing healthcare expenditure by governments along with rising prevalence of diabetes is expected to drive growth over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period due to an increase in diabetic population and growing pharmaceutical industry coupled with improving economic conditions in emerging countries such as China, India, South Korea & Japan. Moreover, increasing R&D activities for new drug development are also expected to drive growth over this period.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for pioglitazone HCL in the coming years.
- Rising awareness about diabetes and its treatment options: There is a growing awareness among people about diabetes and its treatment options, including pioglitazone HCL. This is likely to boost the demand for this drug in the coming years.
- Growing number of clinical studies supporting the use of pioglitazone HCL: There are several clinical studies that have shown the efficacy and safety of pioglitazone HCL in treating type 2 diabetes mellitus patients. This is likely to increase its adoption in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pioglitazone HCL Market Research Report
By Type
15 mg, 30 mg, 45 mg
By Application
Industrial, Pharmaceuticals, Others
By Companies
BOC Sciences, London Drugs, Abhilasha Pharma Pvt Ltd, Tocris, ChemSpider, Rxlist, Beijing Taiyang, Sigma Aldrich, Hubei Jusheng Technology, Xiamen Hisunny Chemical, BOC Sciences, SHANDONG JIULONG HISINCE PHARMACEUTICAL, Hubei YuanCheng SaiChuang Technology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Pioglitazone HCL Market Report Segments:
The global Pioglitazone HCL market is segmented on the basis of:
Types
15 mg, 30 mg, 45 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Industrial, Pharmaceuticals, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BOC Sciences
- London Drugs
- Abhilasha Pharma Pvt Ltd
- Tocris
- ChemSpider
- Rxlist
- Beijing Taiyang
- Sigma Aldrich
- Hubei Jusheng Technology
- Xiamen Hisunny Chemical
- BOC Sciences
- SHANDONG JIULONG HISINCE PHARMACEUTICAL
- Hubei YuanCheng SaiChuang Technology
Highlights of The Pioglitazone HCL Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 15 mg
- 30 mg
- 45 mg
- By Application:
- Industrial
- Pharmaceuticals
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pioglitazone HCL Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pioglitazone HCL is a medication used to treat type 2 diabetes. It works by helping the body to control blood sugar levels. Pioglitazone HCL can also help to reduce the risk of heart disease and stroke.
Some of the key players operating in the pioglitazone hcl market are BOC Sciences, London Drugs, Abhilasha Pharma Pvt Ltd, Tocris, ChemSpider, Rxlist, Beijing Taiyang, Sigma Aldrich, Hubei Jusheng Technology, Xiamen Hisunny Chemical, BOC Sciences, SHANDONG JIULONG HISINCE PHARMACEUTICAL, Hubei YuanCheng SaiChuang Technology.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pioglitazone HCL Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pioglitazone HCL Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pioglitazone HCL Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pioglitazone HCL Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pioglitazone HCL Market Size & Forecast, 2020-2028
4.5.1 Pioglitazone HCL Market Size and Y-o-Y Growth
4.5.2 Pioglitazone HCL Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 15 mg
5.2.2 30 mg
5.2.3 45 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Industrial
6.2.2 Pharmaceuticals
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pioglitazone HCL Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pioglitazone HCL Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 15 mg
9.6.2 30 mg
9.6.3 45 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Industrial
9.10.2 Pharmaceuticals
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 15 mg
10.6.2 30 mg
10.6.3 45 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Industrial
10.10.2 Pharmaceuticals
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 15 mg
11.6.2 30 mg
11.6.3 45 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Industrial
11.10.2 Pharmaceuticals
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 15 mg
12.6.2 30 mg
12.6.3 45 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Industrial
12.10.2 Pharmaceuticals
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 15 mg
13.6.2 30 mg
13.6.3 45 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Industrial
13.10.2 Pharmaceuticals
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pioglitazone HCL Market: Competitive Dashboard
14.2 Global Pioglitazone HCL Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BOC Sciences
14.3.2 London Drugs
14.3.3 Abhilasha Pharma Pvt Ltd
14.3.4 Tocris
14.3.5 ChemSpider
14.3.6 Rxlist
14.3.7 Beijing Taiyang
14.3.8 Sigma Aldrich
14.3.9 Hubei Jusheng Technology
14.3.10 Xiamen Hisunny Chemical
14.3.11 BOC Sciences
14.3.12 SHANDONG JIULONG HISINCE PHARMACEUTICAL
14.3.13 Hubei YuanCheng SaiChuang Technology
